TLX Telix Pharmaceuticals Limited

NEUTRAL Impact: 4/10 PRESS-RELEASE
Horizon months Filed Jun 2, 2026 Processed 10d 21h ago Wire GlobeNewswire
Press release: contract
Latest settled — T+1d ⚠ clustered
TLX ▼ -4.26% at T+1d
NEUTRAL call ✗ call lost -4.26% · α vs SPY -3.54% · entry $9.16 → $8.77
Next anchor: T+5d due 4d ago
Currently $9.56 · +4.37% from $9.16 entry
Entry anchored
Jun 2, 2026
via day open
T+1d
-4.26%
call -4.26% · α -3.54%
$8.77
settled 10d ago
T+5d
call — · α —
due 4d ago
T+20d
call — · α —
in 18d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboration integrating Telix's radiopharmaceuticals with United Imaging's scanner platforms, initially focusing on TLX101-Px (Pixclara) in the U.S. The collaboration is exploratory and non-binding, with no financial terms disclosed, and does not change Telix's near-term revenue or regulatory trajectory.

Actionable Insight

This is a non-binding exploratory MOU with no financial terms — unlikely to move the stock near-term. The key catalyst for TLX remains the PDUFA date of September 11, 2026 for TLX101-Px. Monitor for any subsequent definitive agreements or expansion announcements.

Key Facts

  • MOU signed with United Imaging Healthcare North America to evaluate integrated theranostics workflows.
  • Initial focus on TLX101-Px (Pixclara, Floretyrosine F 18) in the U.S., with potential expansion to other products and markets.
  • TLX101-Px NDA accepted by FDA in April 2026, with PDUFA goal date of September 11, 2026.
  • No financial terms, revenue commitments, or binding obligations disclosed.
  • Collaboration includes scanning protocol optimization, workflow tools, and pilot programs.

Financial Impact

No financial terms disclosed; collaboration is exploratory and non-binding.

Risk Factors

  • MOU is non-binding and may not lead to a definitive agreement.
  • TLX101-Px has not received marketing authorization in any jurisdiction; FDA decision pending.
  • No revenue or cost-sharing details provided; financial impact uncertain.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304988
8 reports for TLX
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+1▲ +2.36%Apr 29, 2026
Filters
Rows
Reports for TLX — sortable, filterable
Type Now
Jun 2, 2026
10d ago
Press Release
NEUTRAL ★ 4/10
$9.16 $8.77▼ −4.26%▼ −3.54%$9.56 (+4.37%)
Jun 1, 2026
11d ago
Press Release
BULLISH ★ 6/10
$9.16 $8.77▼ −4.26%▼ −3.54%$9.56 (+4.37%)
May 18, 2026
25d ago
Press Release
BULLISH ★ 6/10
$10.17 $10.28▲ +1.08%▲ +0.04%$9.56 (−6.00%)
May 15, 2026
28d ago
Press Release
NEUTRAL ★ 4/10
$10.56 $10.28▼ −2.65%▼ −2.59%$9.56 (−9.47%)
May 4, 2026
5w ago
Press Release
BULLISH ★ 5/10
$11.04 $11.11▲ +0.63%▼ −0.75%$9.56 (−13.41%)
Apr 29, 2026
6w ago
Press Release
BULLISH ★ 7/10
$11.00 $11.26▲ +2.36%▲ +2.14%$9.56 (−13.09%)
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 7/10
$10.33 $10.19▼ −1.36%▼ −0.96%$9.56 (−7.45%)
Apr 13, 2026
8w ago
Press Release
BULLISH ★ 7/10
$11.24 $10.70▼ −4.80%▼ −6.01%$9.56 (−14.95%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (53h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access